Research Article
Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction
Table 1
Baseline characteristics.
| | | No GP IIb/IIIa inhibitor used () | GP IIb/IIIa inhibitor used () | Significance () |
| | Age | 65.1 (±12.4) | 62.0 (±12.2) | <0.001* | | Gender (female) | 501 (28.6%) | 336 (26.0%) | 0.119 | | Previous MI | 577 (32.9%) | 352 (27.2%) | 0.001* | | Previous CABG | 160 (9.12%) | 94 (7.26%) | 0.073 | | Previous PCI | 336 (19.2%) | 154 (11.9%) | <0.001* | | Current smoker | 417 (23.8%) | 430 (33.2%) | <0.001* | | Hypertension | 1079 (61.6%) | 700 (54.1%) | <0.001* | | Hypercholesterolaemia | 1044 (59.6%) | 617 (47.4%) | <0.001* | | DM | 448 (25.6%) | 315 (24.3%) | 0.447 | | Renal disease | 103 (5.88%) | 36 (2.78%) | <0.001* | | Previous CVA | 63 (3.59%) | 26 (2.01%) | 0.012* | | PVD | 82 (4.68%) | 38 (2.94%) | 0.014* | | Cardiogenic shock | 20 (1.14%) | 21 (1.62%) | 0.269 |
|
|
value < 0.05.
|
